Human Hepatitis B Immunoglobulin

Grand Shuyang Life Sciences (Chengdu) Co., Ltd. traces its roots to 1985, when it was founded as Chengdu Shuyang Pharmaceutical Factory under the Chengdu Military Region; after several reorganizations - including a stint as Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. within the China Grand Group and a 2008 conversion to a joint-stock company - it adopted its current name in 2024. The company manufactures and trades protein, antigen, and polypeptide products for markets in Central/South America, Eastern Europe, Asia, the Middle East, and Africa, and has developed a proprietary preservative-free dual viral inactivation process protected by patents in the United States, Australia, and China. Its own-brand R&D team and production capacity underpin a reputation built on recognized certifications, buyer-specific customization, and quality service, with payment typically handled via T/T.